Avalo Therapeutics, Inc.

AVTX

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
FP01	Phase 2	Chronic Refractory Cough	-
AVTX-002	Phase 2	Non-Eosinophilic Asthma	-
CERC-301	Phase 2	Major Depressive Disorder	-
AVTX-009 Regimen 1	Phase 2	Hidradenitis Suppurativa	-
Placebo	Phase 2	Major Depressive Disorder	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

March 2026~AVTX-009 Regimen 1

Primary completion for AVTX-009 Regimen 1 trial (NCT06603077) in Hidradenitis Suppurativa

Regulatory Approvals

AVTX News